Recursion Pharmaceuticals Inc (NASDAQ: RXRX) is -36.41% lower on its value in year-to-date trading and has touched a low of $5.89 and a high of $15.74 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RXRX stock was last observed hovering at around $6.10 in the last trading session, with the day’s gains setting it 0.17%.
Currently trading at $6.27, the stock is -7.00% and -5.81% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 9.28 million and changing 2.79% at the moment leaves the stock -25.01% off its SMA200. RXRX registered -11.06% loss for a year compared to 6-month loss of -34.07%. The firm has a 50-day simple moving average (SMA 50) of $6.6577 and a 200-day simple moving average (SMA200) of $8.375075.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -7.25% gain in the last 1 month and extending the period to 3 months gives it a -17.72%, and is -17.28% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.43% over the week and 6.87% over the month.
Profit margin for the company is -579.51%. Distance from 52-week low is 6.54% and -60.17% from its 52-week high. The company has generated returns on investments over the last 12 months (-63.09%).
with sales reaching $18.17M over the same period.The EPS is expected to grow by 1.97% this year, but quarterly earnings will post 59.95% year-over-year. Quarterly sales are estimated to grow 66.85% in year-over-year returns.
Recursion Pharmaceuticals Inc (RXRX) Top Institutional Holders
351.0 institutions hold shares in Recursion Pharmaceuticals Inc (RXRX), with institutional investors hold 98.53% of the company’s shares. The shares outstanding are 226.26M, and float is at 221.54M with Short Float at 28.18%. Institutions hold 94.07% of the Float.
The top institutional shareholder in the company is ARK INVESTMENT MANAGEMENT LLC with over 28.14 million shares valued at $211.07 million. The investor’s holdings represent 11.924% of the RXRX Shares outstanding. As of 2024-06-30, the second largest holder is BAILLIE GIFFORD & CO with 26.59 million shares valued at $199.42 million to account for 11.266 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 21.56 million shares representing 9.1334% and valued at over $161.67 million, while BLACKROCK INC. holds 7.3342 of the shares totaling 17.31 million with a market value of $129.83 million.
Recursion Pharmaceuticals Inc (RXRX) Insider Activity
The most recent transaction is an insider sale by Gibson Christopher, the company’s Chief Executive Officer. SEC filings show that Gibson Christopher sold 20,000 shares of the company’s common stock on Nov 13 ’24 at a price of $7.74 per share for a total of $0.15 million. Following the sale, the insider now owns 0.76 million shares.
Recursion Pharmaceuticals Inc disclosed in a document filed with the SEC on Nov 14 ’24 that Gibson Christopher (Chief Executive Officer) sold a total of 20,000 shares of the company’s common stock. The trade occurred on Nov 14 ’24 and was made at $7.35 per share for $0.15 million. Following the transaction, the insider now directly holds 0.76 million shares of the RXRX stock.
Still, SEC filings show that on Nov 12 ’24, Borgeson Blake (Director) disposed off 11,447 shares at an average price of $7.64 for $87457.0. The insider now directly holds 7,066,113 shares of Recursion Pharmaceuticals Inc (RXRX).
